Skip to main
RNA

RNA Earnings Dates & Reports

RNA Most Recent Earnings

Report Date
Period EndingQ3 2025
Est. EPS-$1.08
Actual EPS-$1.27
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

RNA Earnings per Share (EPS) History

Signup for full access
Browse free

RNA Latest Earnings

The value each RNA share was expected to gain vs. the value each share gained.

RNA reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of -$1.27. This exceeded analysts' expectations of -$1.08 by 17.59%, marking a Miss.

For comparison, Atrium Therapeutics Inc reported EPS of -$0.65 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$1.26.

RNA Earnings History

Earnings
Est. EPSActual EPSSurprise
Q4 2025
-$1.26
Q3 2025
-$1.08-$1.27+17.59%
Q2 2025
-$0.95-$1.21+27.37%
Q1 2025
-$0.88-$0.90+2.27%
Q4 2024
-$0.78-$0.80+2.56%
View all

RNA Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Atrium Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

RNA Earnings FAQs

RNA last reported earnings on Nov 10, 2025 for Q3 2025, posting an EPS of -$1.27, which Miss the estimate of -$1.08 by 17.59%.

For Q3 2025, RNA reported an EPS of -$1.27, missing analysts' estimate of -$1.08 by 17.59%.

For Q3 2025, RNA Miss expectations with an actual EPS of -$1.27 vs. an estimated EPS of -$1.08.

Following the last earnings report on Nov 10, 2025, RNA's stock price moved — from — to —.

The next RNA earnings call is scheduled for Mar. 13, 2026, where executives will discuss financial results and outlook.

Atrium Therapeutics Inc (RNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.